Non-melanoma skin cancers trials

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This Mayo Clinic-sponsored trial, currently recruiting, tests delivering cancer treatment at home versus in the clinic for adults with advanced cancer who are already receiving standard therapy. It aims to learn how the home-based approach affects patient experiences, preferences, comfort with home infusions, and overall quality of life compared with usual clinic care. The study also looks at safety of home administration with remote monitoring, and outcomes like emergency room visits, hospitalizations, and overall survival. Eligible participants are adults with various cancer types on eligible regimens, but those who need 24/7 assistance with daily activities, are currently inpatient, or have uncontrolled illness may be excluded.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Liquid Biomarker Study in Melanoma and Non-Melanoma Skin Cancers is being studied. Conditions: Skin Cancer, Melanoma (Skin Cancer), Basal Cell Carcinoma of Skin +3 • Eligibility: Inclusion Criteria: * Age ≥18 years. * Participants must meet at least one of the following criteria: * Finding suspicious of melanoma or non-melanoma skin cancer based on…. Goal: The goal of this observational study is to study blood samples and compare them to other biospecimens and clinical outcomes in participants who have melanoma or non-melanoma skin cancers. The main question it aims to answer is: * Are blood based signatures able to predict progression-free survival (PFS)? Phase/Status/Sponsor: Unknown phase; RECRUITING; University of Wisconsin, Madison.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Personalised Immunotherapy Platform is being studied. Conditions: Melanoma, Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma +2 • Eligibility: MELANOMA: Inclusion Criteria: 1. Written informed consent to participation for the use of tumour tissue, blood and stool and collection of standard clinical data. 2. Histologically confirmed resected…. Goal: This is a non-interventional study to prospectively test a suite of predictive biomarker models of immunotherapy resistance in patients with melanoma, non-melanoma skin cancers and other solid tumours. The study will evaluate the documentation, processes, accuracy and utility of the predictive biomarker model in clinical practice. Phase/Status/Sponsor: Unknown phase; RECRUITING; Melanoma Institute Australia.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer is being studied. Conditions: Cutaneous Squamous Cell Carcinoma, SCC - Squamous Cell Carcinoma, Basal Cell Carcinoma +16 • Eligibility: Inclusion Criteria: * Age 18 or over * Histologically or cytologically documented advanced or metastatic cancer that has relapsed from or is refractory to standard treatment in two…. Goal: Participants of this study will have a diagnosis of a solid tumor cancer that has come back to its original location or spread beyond its original location (advanced), came back (relapsed) or worsened (refractory) after standard treatments, or no standard treatments are available for the participants' cancer. The purpose of this study if to find the highest dose of MQ710 that causes few or mild side effects in participants with a solid tumor cancer diagnosis. Phase/Status/Sponsor: Unknown phase; RECRUITING; Memorial Sloan Kettering Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 1B/2 Study of RP1 in Solid Organ Transplant Patients With Advanced Cutaneous Malignancies is being studied. Conditions: Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, Basal Cell Carcinoma +1 • Eligibility: Key Inclusion Criteria: 1. Voluntary agreement to provide written informed consent prior to any study procedures and the willingness and ability to comply with all aspects of the…. Goal: This Phase 1B/2 study is a multicenter, open-label, study of RP1 to investigate the (a) objective response rate, in addition to (b) safety and tolerability of RP1 for the treatment of advanced cutaneous malignancies in up to 65 evaluable organ transplant recipients. This will include patients with either previous renal, hepatic, heart, lung, or other solid organ transplantation or hematopoietic cell transplant and experiencing subsequent documented locally advanced or metastatic cutaneous malignancies. Phase/Status/Sponsor: Unknown phase; RECRUITING; Replimune Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Beta-only IL-2 ImmunoTherapY Study is being studied. Conditions: Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma +34 • Eligibility: Key Inclusion Criteria: 1. Aged at least 18 years (inclusive at the time of informed consent). 2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.…. Goal: This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; Medicenna Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Skin Cancer and Hyperthermia and Radiotherapy is being studied. Conditions: Basal Cell Carcinoma, Squamous Cell Carcinoma Skin, Non-melanoma Skin Cancer • Eligibility: Inclusion Criteria: * Personally signed and dated written informed consent * Histologically confirmed invasive non-melanoma skin cancer (NMSC), including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC)…. Goal: The SAHARA trial assesses wether combining ultrahypofractionated accelerated radiotherapy (RT) with hyperthermia is as effective as standard hypofractionated high-dose radiation in treating non-melanoma skin cancer (NMSC). Phase/Status/Sponsor: Unknown phase; RECRUITING; Kantonsspital Winterthur KSW.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia With History of Non-melanoma Skin Cancers is being studied. Conditions: Chronic Lymphocytic Leukemia, Non-melanoma Skin Cancer (NMSC) • Eligibility: Inclusion Criteria: * Male or female subject aged ≥ 18 years. * Confirmed diagnosis of CLL or small lymphocytic leukemia (SLL) per iwCLL 2018 criteria. * History of…. Goal: This is a randomized, phase II, double-blind, placebo-controlled trial with planned crossover to the intervention arm after 1 year. Consenting patients with CLL who have had at least one NMSC diagnosed in the past year will be randomized to receive either oral nicotinamide 500 mg twice daily (BID) for 1 year or oral placebo 1 tablet twice daily for 1 year. Phase/Status/Sponsor: Unknown phase; RECRUITING; University of Utah.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This study tests the combination of nivolumab and ipilimumab in adults with rare cancers to see if it can shrink tumors or slow their growth. - It includes many different rare tumor types in separate groups, plus a PD-L1–amplified cohort that uses nivolumab alone, and it measures how often tumors respond using standard criteria. - The trial also looks at safety, overall survival, and progression-free survival across cohorts. - Eligible participants must have progressed after prior therapy and generally cannot have active brain metastases or uncontrolled autoimmune disease; some cohorts have additional specific requirements or exclusions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Identification of Olfactory Biomarkers of Skin Cancer From Skin Odor Samples: a Pilot Study is being studied. Conditions: Identify Volatile Biomarkers Specific to Malignant Melanoma, Basal Cell Carcinoma and Squamous Cell Carcinoma, Verify That the Volatile Biomarkers Identified Derive From Metabolic Changes in Body Odour and Not Just From Changes in the Surface of Cancerous Lesions • Eligibility: Inclusion Criteria: * For patients 1. Adult patient (age ≥ 18 years), 2. Patient with a diagnosis of skin cancer of the malignant melanoma, basal cell carcinoma or…. Goal: The aim of this research is to determine which volatile organic compounds (odors) are associated with different skin cancers. To this end, odor samples will be taken from various parts of the body, from patients with skin cancers and from "healthy" subjects who have no skin cancer. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Association pour la Recherche Clinique et Immunologique.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

D-OCT for Detection and Subtyping of BCC: a Diagnostic Cohort Study is being studied. Conditions: Basal Cell Carcinoma, Optical Coherence Tomography • Eligibility: Inclusion Criteria: * 18+ years * Lesions suspect for non-melanoma skin cancer or premalignancy * Patient underwent D-OCT scan and biopsy conform regular care Exclusion Criteria: * Patient…. Goal: The current gold standard for diagnosing basal cell carcinoma (BCC) is the histopathological examination of biopsy specimen. However, non-invasive imaging modalities such as optical coherence tomography (OCT) may replace biopsy if BCC presence and its subtype can be established with high confidence. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Maastricht University Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Skin Tumor Biomarkers by Mass Spectrometry Imaging is being studied. Conditions: Skin Cancer, Squamous Cell Carcinoma, Basal Cell Carcinoma +1 • Eligibility: Inclusion Criteria: * Patients above 18 years of age. * Patients presenting with AKs, SCCs and BCCs. * Written informed consent obtained from patient. Exclusion Criteria: • Immunosuppressed…. Goal: The purpose of the study is to investigate the ability of mass spectrometry imaging to locate aggregates of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) ex-vivo, and to distinguish areas containing these carcinomas from normal skin. It is suggested that non-melanoma skin cancer (NMSC) cells show a different profile of endogenous lipids than healthe skin tissue which can be used as identifying biomarkers. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Bispebjerg Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Bioelectric Field Imaging in Diagnosing Melanoma and Other Skin Cancers in Patients With Skin Lesions is being studied. Conditions: Melanoma (Skin), Non-melanomatous Skin Cancer • Eligibility: DISEASE CHARACTERISTICS: * Suspected malignant skin lesion * Seeking treatment for skin lesion at the VA Medical Center PATIENT CHARACTERISTICS: * Not pregnant * No acute illness, including…. Goal: RATIONALE: New diagnostic procedures, such as bioelectric field imaging, may help find and diagnose melanoma and other skin cancers. It may also be a less invasive way to check for skin cancer. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Eastern Virginia Medical School.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

FACE-Q in Facial Reconstructive Surgery: A Prospective Database is being studied. Conditions: Skin Cancer, Basal Cell Skin Cancer Skin Cancer, Non-Melanoma Skin Cancers - Squamous Cell Carcinoma Patient Satisfaction • Eligibility: Inclusion Criteria: i. Age 18 years or older ii. Use of any module of the FACE-Q scale to measure a patient-reported outcome iii. Ability to provide informed consent…. Goal: The primary objective is to establish a prospective database of clinical information, FACE-Q scores, and patient photographs (as appropriate) to enhance the understanding and practice of facial plastic and reconstructive surgery. Phase/Status/Sponsor: Unknown phase; UNKNOWN; McMaster University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Comparison of Skin Grafts Versus Local Flaps for Facial Skin Cancer From the Patient Perspective: A Feasibility Study is being studied. Conditions: Skin Cancer, Basal Cell, Skin Cancer, Skin Cancer, Non-Melanoma +2 • Eligibility: Inclusion Criteria: Patients will be included in the study if: * they are 18 years or older * presenting for treatment of a suspected non-melanoma facial skin cancer,…. Goal: A prospective single-centered feasibility study will be conducted. The purpose of the feasibility study is to define the variables to be included in a subsequent pilot study, assess the feasibility of conducting a prospective cohort study, and the logistics for the study (i.e., training, patient recruitment, data collection, statistical analysis, etc.). Phase/Status/Sponsor: Unknown phase; UNKNOWN; McMaster University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Intratumoral Administration of Daromun in Non-melanoma Skin Cancer Patients is being studied. Conditions: Carcinoma, Basal Cell, Carcinoma, Cutaneous Squamous Cell • Eligibility: Inclusion Criteria: * High-risk, localized (non-metastatic, node negative, single or multifocal) BCC or cSCC amenable to intratumoral injection. * Patients with injectable and measurable regional cutaneous or subcutaneous…. Goal: This clinical phase II study is designed to investigate the efficacy of intratumorally administered L19IL2/L19TNF in patients with injectable lesions of BCC or cSCC. Favorable tumor responses following intralesional treatment with L19IL2/L19TNF have been observed in patients with injectable melanoma lesions of stage III or IV, for injected and non-injected lesions. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Philogen S.p.A..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin Cancers is being studied. Conditions: Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Non-Melanoma Skin Cancers • Eligibility: Inclusion Criteria: * Life expectancy ≥ 3 months at recruitment * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 at the time of study treatment initiation. *…. Goal: In this clinical phase I, non-randomized, open-label, uncontrolled, interventional, multi-center trial, 20 adult subjects (≥ 18 years of age) with advanced non-melanoma skin cancers will receive a fixed dose of 0.1 mg of IFx-Hu2.0 intralesionally as monotherapy in up to three lesions at up to three time points. Subjects will be observed for any acute adverse events (AEs) post injection and for any delayed AEs at Day 28, 35 and/or 42 ± 7 days, depending on the cohort (exposure escalation and expansion design). Phase/Status/Sponsor: Unknown phase; COMPLETED; TuHURA Biosciences, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Comparison of 3 in Vivo Microscopic Imaging Techniques for the Diagnosis of Pigmented Tumors is being studied. Conditions: Basal Cell Carcinoma, Lentigo Maligna, Melanoma +3 • Eligibility: Inclusion Criteria: * Patients with a pigmented skin lesion of more than 3mm diameter which have benefited systematically of all 3 imaging techniques at the same time, followed…. Goal: Reflectance confocal microscopy (RCM) is the reference in vivo imaging technique for identifying malignant melanocytic tumors prior to surgical excision. However, it is not widely used due to its high cost and highly technical and time-consuming nature. Phase/Status/Sponsor: Unknown phase; COMPLETED; Centre Hospitalier Universitaire de Saint Etienne.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Optical Frequency Domain Imaging for Non-melanoma Skin Cancers is being studied. Conditions: Non-Melanoma Skin Cancer (NMSC) • Eligibility: Inclusion Criteria: 1. Male or female subjects with Fitzpatrick skin type I-VI 2. Subjects with ages between 18 and 80 years of age 3. Presence of at least…. Goal: The purpose of this research study is to find out if a non-invasive imaging device called Optical Frequency Domain Imaging (OFDI) can help doctors to see the tissue and blood vessels that are related to non-melanoma skin cancers. OFDI was designed to see microscopic details of your skin without needing to use any invasive techniques such as surgery or biopsy. Phase/Status/Sponsor: Unknown phase; COMPLETED; Massachusetts General Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Electronic Brachytherapy for the Treatment of NMSC is being studied. Conditions: Basal Cell Carcinoma, Squamous Cell Carcinoma • Eligibility: Inclusion Criteria: * Patient has signed the informed consent form * Pathological diagnosis confirmed of squamous cell or basal cell carcinoma * Histopathological Grade: G1 (well differentiated), G2…. Goal: The objective of this study is to record recurrence in patients treated for nonmelanoma (basal cell and squamous cell carcinomas) skin cancer using the Xoft Axxent Electronic Brachytherapy System. Additional objectives include evaluate the appearance of the treated area in patients treated for nonmelanoma skin cancer using the Xoft Axxent Electronic Brachytherapy System and record the occurrence of radiation therapy related skin changes in patients treated for nonmelanoma skin cancer. Phase/Status/Sponsor: Unknown phase; COMPLETED; Xoft, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain is being studied. Conditions: Cancer • Eligibility: Inclusion Criteria: * Male or female, ≥ 18 years of age. * Diagnosis of cancer. * Opioid-tolerant. Subjects who were opioid tolerant were those taking ≥ 60 mg…. Goal: This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain. The study medication is administered under the tongue as a simple spray and can be self-administered by patients or assisted by their caregivers. Phase/Status/Sponsor: Unknown phase; COMPLETED; INSYS Therapeutics Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer is being studied. Conditions: Bladder Cancer, Breast Cancer, Colorectal Cancer +9 • Eligibility: DISEASE CHARACTERISTICS: * Diagnosis of 1 of the following: * Histologically confirmed advanced primary or malignant solid tumor refractory to standard therapy or for which no curative standard…. Goal: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of 17-N-allylamino-17-demethoxygeldanamycin in treating patients with refractory advanced solid tumors or hematologic cancers. Phase/Status/Sponsor: Unknown phase; COMPLETED; Memorial Sloan Kettering Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma is being studied. Conditions: Cancer • Eligibility: DISEASE CHARACTERISTICS: * Histologically confirmed malignancy that is metastatic or unresectable and for which no effective standard curative or palliative therapy exists * Brain metastases allowed provided both…. Goal: RATIONALE: MS-275 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of MS-275 in treating patients with advanced solid tumors or lymphoma. Phase/Status/Sponsor: Unknown phase; COMPLETED; National Institutes of Health Clinical Center (CC).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor is being studied. Conditions: Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gastric Cancer +3 • Eligibility: DISEASE CHARACTERISTICS: * Histologically confirmed solid tumor * Progressive disease on standard therapy, including: * Locally advanced, unresectable primary or recurrent tumor OR * Metastatic disease * Previously…. Goal: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Phase/Status/Sponsor: Unknown phase; COMPLETED; National Institutes of Health Clinical Center (CC).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Thalidomide and Docetaxel in Treating Patients With Advanced Cancer is being studied. Conditions: Cancer • Eligibility: DISEASE CHARACTERISTICS: * Histologically confirmed malignancy not amenable to curative surgery, radiotherapy, or chemotherapy * Tumor types may include any of the following: * Any solid tumor including,…. Goal: RATIONALE: Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Phase/Status/Sponsor: Unknown phase; COMPLETED; Case Comprehensive Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

An Exploratory Study on the Treatment of Chronic Obstructive Pulmonary Disease With Autologous Bronchial Basal Cell Transplantation is being studied. Conditions: Cell Transplantation • Eligibility: Inclusion Criteria: 1. aged between 18 to 70 years 2. according to the guideline criteria, the diagnosis of COPD: ①There is a chronic cough, sputum or gas breathing…. Goal: Chronic obstructive pulmonary disease(COPD)is characterized by recurrent cough, expectoration and asthma, and eventually develop chronic pulmonary heart disease ,chronic respiratory failure and even death. The current clinical treatments for these patients are symptomatic treatment cannot solve the problem of the damaged lung structure fundamentally. Phase/Status/Sponsor: Unknown phase; COMPLETED; Huai'an No.1 People's Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy is being studied. Conditions: Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma +41 • Eligibility: Inclusion Criteria: * Provides written informed consent * Diagnosed with advanced NSCLC, breast cancer, GBM or other cancers (such as head and neck, colorectal, pancreatic, renal cancers); patients…. Goal: The purpose of the study is to conduct research of a new PET radiopharmaceutical in cancer patients. The uptake of the novel radiopharmaceutical 18F-FPPRGD2 will be assessed in study participants with glioblastoma multiforme (GBM), gynecological cancers, and renal cell carcinoma (RCC) who are receiving antiangiogenesis treatment. Phase/Status/Sponsor: Unknown phase; COMPLETED; Sanjiv Sam Gambhir.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) is being studied. Conditions: Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Estrogen Receptor-negative Breast Cancer +85 • Eligibility: Inclusion Criteria: * Part I (closed to accrual as of 6/8/2007) * Histologically confirmed solid tumor that is metastatic or unresectable for which standard curative measures do not…. Goal: This phase I trial is studying the side effects and best dose of giving 7-hydroxystaurosporine together with irinotecan hydrochloride in treating patients with metastatic or unresectable solid tumors, including triple-negative breast cancer (currently enrolling only patients with triple-negative breast cancer since 6/8/2007). Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Phase/Status/Sponsor: Unknown phase; COMPLETED; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Spanish Registry of Mohs Surgery is being studied. Conditions: Skin Neoplasms, Carcinoma, Basal Cell, Carcinoma, Squamous Cell +4 • Eligibility: Inclusion Criteria: * All consecutive patients considered for Mohs surgery Exclusion Criteria: * Under 18 years-old * Legally incompetent. Goal: REGESMOHS (Registro Español de cirugía de Mohs) aims at describing effectiveness of Mohs surgery, and patient, tumor and technique factors related to adverse events and tumor recurrence. REGESMOHS is a prospective cohort, including all patients considered for Mohs surgery in participating centers. Phase/Status/Sponsor: Unknown phase; COMPLETED; Fundación Academia Española de Dermatología.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo is being studied. Conditions: Erysipelas, Impetigo, Herpes Zoster +7 • Eligibility: Inclusion Criteria: * Subjects currently working at the Local Health Authority of the province of Bergamo Exclusion Criteria: * Subjects who are not able to use the tele-dermatology…. Goal: The purpose of this study is to demonstrate the validity and utility of a tele-dermatology system in the midterm periodic screening of non-widespread skin lesions of recent onset or for which a specialized early classification is deemed to change the prognosis - including precancerous skin lesions as well as melanoma and non-melanoma skin cancers - compared to control visits at fixed follow-up. Phase/Status/Sponsor: Unknown phase; COMPLETED; Centro Studi Gised.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC) is being studied. Conditions: Melanoma, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma of the Skin +3 • Eligibility: Inclusion Criteria: * Histologically confirmed diagnosis of melanoma, squamous head and neck cancer, sarcoma, squamous cell carcinoma of the skin, basal cell skin cancer, or breast cancer *…. Goal: The purpose of this study is to test the safety of a course of injections containing Poly-ICLC in patients with advanced solid tumors that can be easily and safely reached with a needle. Poly-ICLC is a compound that has been used to help the body in its fight against cancer. Phase/Status/Sponsor: Unknown phase; TERMINATED; Nina Bhardwaj.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Eversion in Dermatologic Surgery: Is Cosmetic Appearance Improved? is being studied. Conditions: Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma • Eligibility: Inclusion Criteria: * Over 18 years of age * Able to give informed consent themselves * Willing to return for follow up visits Exclusion Criteria: * Mentally handicapped…. Goal: The investigators hypothesize that everting wound edges while suturing surgical sites will result in more aesthetic scars. Additionally, we also hypothesize that small to moderate wound irregularities present at 3 months will resolve by 6 months after surgery with no intervention Phase/Status/Sponsor: Unknown phase; COMPLETED; University of California, Davis.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Ultrasound Biomicroscopy - Apoptosis is being studied. Conditions: Lymphoma, Lymphoma, Non-Hodgkin, Melanoma +1 • Eligibility: Inclusion Criteria: * lymphoma patients with superficial lesions prior to starting chemotherapy or after relapse of disease * patients with superficial melanoma lesions * patients with superficial basal…. Goal: A group of researchers at the Ontario Cancer Institute/Princess Margaret Hospital have discovered that a very specific form of cell death 'apoptosis' can be detected using high-frequency ultrasound imaging. This type of cell death is recognized to occur in tumours in response to various different chemotherapeutic drugs and in response to radiation therapy. Phase/Status/Sponsor: Unknown phase; COMPLETED; University Health Network, Toronto.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

How Microbes and Metabolism May Predict Skin Cancer Immunotherapy Outcomes is being studied. Conditions: Autoimmunity, Melanoma, Merkel Cell Carcinoma +3 • Eligibility: Inclusion Criteria: * ≥18 years of age. * Diagnosis of skin cancer. * Planning to initiate or already on ANY type of immunotherapy. * Able to provide urine…. Goal: The purpose of this research study is to examine the relationship between the microbiota (microscopic organisms) in the gut and the activity of the immune system during skin cancer immunotherapy. Phase/Status/Sponsor: Unknown phase; TERMINATED; Washington University School of Medicine.

This summary may be inaccurate. Verify against ClinicalTrials.gov.